Oligoastrocytic tumors

May show changes typical for diffuse astrocytoma (TP53 mutation & LOH on 17p) or for ODG (LOH on 1p and 19q). No molecular genetic markers have been identified to distinguish oligoastrocytoma from either astrocytoma or ODG. Unlike ODG, the prognostic/therapeutic value of LOH on 1p is less clear.

33–41% have a component of ependymal or neoplastic astrocytic cells (so called oligoastrocytomas or mixed gliomas or collision tumors.